TokenPost·
Beam Therapeutics Reports Positive Topline Data From Sickle Cell Trial
The Phase 1/2 BEACON study met its primary efficacy endpoint and all primary safety endpoints at an interim analysis.
More news
- TokenPostZeta Global Shares Rise 7% After Q3 Results and Analyst Updates
- TokenPostEther Tops 2,100 USDT on OKX in Nov. 11 Market Snapshot
- Bitcoin.com NewsBitcoin Price Reclaims $74K After CPI Sell-Off Sparks Volatility
- TokenPostTwo People Say Alice Huang-Linked Firms Obtained at Least $7.5 Billion in Nvidia GPUs
- TokenPostSandisk Shares Gain 16% as Memory and Hardware Stocks Strengthen
- UnchainedKraken Parent Expands Beyond US Names With Over 200 UK and EU Stocks